piperidines and Hyperpigmentation

piperidines has been researched along with Hyperpigmentation* in 3 studies

Trials

1 trial(s) available for piperidines and Hyperpigmentation

Article	Year
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Archives of dermatology, 2012, Volume: 148, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Female; Folliculitis; Hand-Foot Syndrome; Humans; Hyperpigmentation; Male; Middle Aged; Photosensitivity Disorders; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms	2012

Other Studies

2 other study(ies) available for piperidines and Hyperpigmentation

Article	Year
Successful laser treatment of vandetanib-associated cutaneous pigmentation. Archives of dermatology, 2011, Volume: 147, Issue:3 Topics: Adult; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hyperpigmentation; Lasers, Solid-State; Piperidines; Protein Kinase Inhibitors; Quinazolines; Skin Pigmentation	2011
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Archives of dermatology, 2009, Volume: 145, Issue:8 Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases.. We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns.. These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed. Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Female; Humans; Hyperpigmentation; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin	2009

Article

Year

Successful laser treatment of vandetanib-associated cutaneous pigmentation.

Archives of dermatology, 2011, Volume: 147, Issue:3

Topics: Adult; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hyperpigmentation; Lasers, Solid-State; Piperidines; Protein Kinase Inhibitors; Quinazolines; Skin Pigmentation

2011

Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.

Archives of dermatology, 2009, Volume: 145, Issue:8

Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases.. We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns.. These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed.

Topics: Aged; Antineoplastic Agents; Dermatitis, Phototoxic; Female; Humans; Hyperpigmentation; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin

2009